BioTheryX to Participate in Upcoming Scientific and Investor Events
SAN DIEGO, Feb. 15, 2021 /PRNewswire/ -- BioTheryX, Inc., a clinical-stage [...]
BioTheryX Appoints Jamie Donadio as Chief Financial Officer
SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- BioTheryX, Inc., [...]
BioTheryX Appoints Robert F. Williamson, III as President and Chief Executive Officer
SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- BioTheryX, Inc., [...]
BioTheryX Announces $35 Million Series D Financing
SAN DIEGO, CA, July 28, 2020 -- BioTheryX, Inc., [...]
BioTheryX, Inc. Announces the Appointment of Professor Yinon Ben- Neriah, M.D., Ph.D., to its Scientific Advisory Board
Accomplished scientist who created BioTheryX's promising lead clinical candidate [...]
BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51
Study is evaluating the safety/tolerability of BTX-A51 in patients [...]
BioTheryX, Inc. Announces the Appointment of BioPharma Finance Veteran Peter N. Crnkovich to Board of Directors
Part of BioTheryX's previously announced plan to continue building [...]
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
BioTheryX plans to continue building out Board of Directors [...]
BioTheryX Announces FDA Approval of IND Application to Initiate Phase 1 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia
Expect Enrollment of Phase 1 Trial to Begin in the [...]
BioRap and BioTheryX Sign Strategic Collaborative Agreement for the Development of Novel Protein Degradation Compounds for the Treatment of Cancer and Immune Disorder
CHAPPAQUA, N.Y., Sept. 08, 2006 /PRNewswire/ -- BioTheryX, Inc. (BTX), [...]